Add Yahoo as a preferred source to see more of our stories on Google. The rare neurogenetic disorder affects 1 in 15,000 people For the first time, Colin Farrell has opened up his home and talked ...

Add Yahoo as a preferred source to see more of our stories on Google. HOLLYWOOD, CALIFORNIA - MARCH 12: Colin Farrell attends the 95th Annual Academy Awards on March 12, 2023 in Hollywood, California.

It wasn’t long after our son Theodore was born that my husband, Daniel, and I noticed how incredibly happy he was. As in “Clap along if you feel like a room without a roof” kind of happy. He barely ...

Colin Farrell revealed that his 20-year-old son, James, has been living with a disorder known as Angelman Syndrome. While speaking with PEOPLE in a recent interview, the Saving Mr. Banks star, 48, ...

Mothers are often encouraged to trust their instincts, especially regarding their children's health. But for Tiffany Young, getting others to take her concerns seriously proved challenging when her ...

Colin Farrell is opening up about life with his 20-year-old son who has Angelman syndrome. The Irish actor is sharing details of James’ life as they prepare for his 21st birthday, a milestone when ...

Actor Colin Farrell has opened up about the difficult decision to move his son James, who has Angelman syndrome, into a long-term care facility. The Oscar-nominated star of The Banshees of Inisherin, ...

CHESHIRE, Conn. (WTNH) — The General Motors charity car show was held on Sunday in Cheshire, benefitting families with children diagnosed with Angelman Syndrome. Quinnipiac students create customized ...

The actor is also launching the Colin Farrell Foundation, which will provide support for adult children who have intellectual disabilities through advocacy, education and innovative programs By Carly ...

Kathryn Ely remembers every detail from the process of her son being diagnosed with Angelman Syndrome, a rare genetic disorder that causes developmental delays, intellectual disabilities, seizures and ...

Ultragenyx Pharmaceutical Inc. announced the dosing of the first patient in its Phase 3 Aspire study, which is investigating the safety and efficacy of GTX-102, an investigational antisense ...